Coherus Oncology
CHRS
201 hedge funds and large institutions have $1.58B invested in Coherus Oncology in 2020 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 82 increasing their positions, 61 reducing their positions, and 21 closing their positions.
62% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 21
34% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 61
7% more funds holding
Funds holding: 188 → 201 (+13)
2% more capital invested
Capital invested by funds: $1.54B → $1.58B (+$33.1M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.12% less ownership
Funds ownership: 122.37% → 120.25% (-2.1%)
75% less call options, than puts
Call options by funds: $742K | Put options by funds: $2.98M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$57.5M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$12.1M |
| 3 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$8.78M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$7.36M |
| 5 |
ACB
Aristotle Capital Boston
Boston,
Massachusetts
|
+$5.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$27.9M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$27.2M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$18.3M |
| 4 |
State Street
Boston,
Massachusetts
|
-$16.4M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.35M |
CHRS Hedge Fund Activity: Q3 2020 in Review
201 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2020, worth a combined $1.58B — up 2.1% from $1.54B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CHRS positions and 21 closed out — a net gain of 13 holders — while 82 added to existing stakes and 61 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $57.5M. The largest seller was Sofinnova Investments, cutting an estimated $27.9M.
- 201 institutional investors held Coherus Oncology (CHRS) as of Q3 2020, up from 188 in Q2 2020.
- Funds reported $1.58B of Coherus Oncology stock for Q3 2020, up 2.1% quarter-over-quarter.
- 34 funds opened new Coherus Oncology positions in Q3 2020 and 21 closed out, a net change of +13 holders.
- The largest Coherus Oncology buyer in Q3 2020 was Perceptive Advisors, an estimated $57.5M added.
- The largest Coherus Oncology seller in Q3 2020 was Sofinnova Investments, an estimated $27.9M sold.
Based on aggregated 13F filings for Q3 2020.